EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

Post-LOE

empagliflozin; metformin hydrochloride

Zydus Lifesciences

ANDAORALTABLET

Approved

Jul 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (empagliflozin; metformin hydrochloride) by Zydus Lifesciences is contain: empagliflozin, a sglt2 inhibitor, and metformin hcl, a biguanide. Approved for type 2 diabetes mellitus, heart failure, chronic kidney disease and 2 more indications. First approved in 2022.

Drug data last refreshed 15h ago

Mechanism of Action

contain: empagliflozin, a SGLT2 inhibitor, and metformin HCl, a biguanide. Empagliflozin Empagliflozin is an inhibitor of SGLT2, the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. By inhibiting SGLT2, empagliflozin reduces…

Indications (5)

Worked on EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at Zydus Lifesciences? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.